20 June 2022: Clinical Research
A Single-Center Retrospective Study to Compare the Efficacy and Safety of Modified FOLFIRINOX with S-1 as Adjuvant Chemotherapy in 71 Patients with Resected Pancreatic Carcinoma
Linhua Yao 1ABCEF , Chengwu Tang 2ABCEF , Wenming Feng 2ABFG , Hanbin Dai 2ABCE*DOI: 10.12659/MSM.937136
Med Sci Monit 2022; 28:e937136
Figure 2 Comparison of overall survival. A total of 46 patients died within 3 years postoperatively (22 from the mFFX group and 24 from the S-1 group). Compared with the S-1 group, the mFFX group obtained a significantly improved 3-year overall survival (P=0.0346) and lower hazard ratio for death (0.5501, 95% CI 0.3029 to 0.9993). MedCalc software (version 15.2.2, MedCalc Software, Ltd.) was used to create the figure.